Menopause already increases a womans risk of muscle loss (sarcopenia) and bone thinning (osteoporosis), so women using GLP1 medications during this transition should be especially vigilant
A 20 percent LDL reduction from a weight-loss-oriented triple agonist is therefore a genuinely new observation and helps explain why retatrutide is being developed across cardiovascular, metabolic, and weight-related indications rather than as a pure obesity asset
Ludvik B, Giorgino F, Jodar E, Frias JP, Fernandez Lando L, Brown K, Bray R, Rodriguez A
Systematic monitoring throughout the GLP-1 journey enables clinicians to assess therapeutic response, identify adverse effects early, and make evidence-based adjustments to optimize outcomes
GLP-1 follows a circadian rhythm, with higher levels during daytime and evening than overnight
The injectable medication is only a once-weekly dose, which may be more convenient if you lead a busier lifestyle